Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gossamer Bio (GOSS) Free Cash Flow (2022 - 2025)

Gossamer Bio (GOSS) has 4 years of Free Cash Flow data on record, last reported at -$36.2 million in Q3 2025.

  • For Q3 2025, Free Cash Flow fell 12.91% year-over-year to -$36.2 million; the TTM value through Sep 2025 reached -$158.5 million, down 11134.02%, while the annual FY2024 figure was -$3.5 million, 97.82% up from the prior year.
  • Free Cash Flow reached -$36.2 million in Q3 2025 per GOSS's latest filing, up from -$47.1 million in the prior quarter.
  • Across five years, Free Cash Flow topped out at $116.3 million in Q2 2024 and bottomed at -$53.6 million in Q1 2022.
  • Average Free Cash Flow over 4 years is -$31.5 million, with a median of -$38.3 million recorded in 2023.
  • Peak YoY movement for Free Cash Flow: soared 404.17% in 2024, then plummeted 140.49% in 2025.
  • A 4-year view of Free Cash Flow shows it stood at -$48.1 million in 2022, then soared by 30.5% to -$33.4 million in 2023, then fell by 6.15% to -$35.5 million in 2024, then dropped by 1.93% to -$36.2 million in 2025.
  • Per Business Quant database, its latest 3 readings for Free Cash Flow were -$36.2 million in Q3 2025, -$47.1 million in Q2 2025, and -$39.8 million in Q1 2025.